157 related articles for article (PubMed ID: 36636684)
1. Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia.
Murakami H; Matsuoka KI; Asano T; Moriyama T; Matsumura A; Fujiwara H; Asada N; Ennishi D; Nishimori H; Fujii K; Fujii N; Toji T; Yoshino T; Maeda Y
Case Rep Oncol; 2022; 15(3):974-979. PubMed ID: 36636684
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
3. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
4. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
Angotzi F; Lessi F; Leoncin M; Filì C; Endri M; Lico A; Visentin A; Pravato S; Candoni A; Trentin L; Gurrieri C
Front Oncol; 2024; 14():1370405. PubMed ID: 38680863
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
Biochem Pharmacol; 2024 Feb; ():116065. PubMed ID: 38373594
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of salvage intensive chemotherapy
Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.
Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S; Hospital MA; Alary AS; Saillard C; Hicheri Y; Mohty B; Rey J; D'Incan E; Charbonnier A; Villetard F; Maisano V; Lombardi L; Ittel A; Mozziconacci MJ; Gelsi-Boyer V; Vey N
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454930
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with
Daido Y; Sugiura H; Ishikawa T; Kuroi T; Okamoto S; Nomura N; Masunari T; Sezaki N; Nannya Y; Ogawa S; Tanimoto M
Case Rep Oncol; 2023; 16(1):999-1006. PubMed ID: 37900854
[TBL] [Abstract][Full Text] [Related]
15. Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia.
Edahiro T; Ureshino H; Chishaki R; Fujino K; Mino T; Yoshida T; Fukushima N; Ichinohe T
EJHaem; 2023 Feb; 4(1):273-275. PubMed ID: 36819153
[TBL] [Abstract][Full Text] [Related]
16. 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.
Mei C; Ye L; Ren Y; Zhou X; Ma L; Xu G; Xu W; Lu C; Yang H; Luo Y; Jiang L; Lang W; Zhu H; Jin J; Tong H
Hematol Oncol; 2023 Aug; 41(3):546-554. PubMed ID: 36516239
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
[No Abstract] [Full Text] [Related]
19. Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
Shiomi I; Nakako S; Nakane T; Ogawa Y; Araki T; Fujitani Y; Yamamura R; Hino M; Nakamae H
Int J Hematol; 2024 Jan; 119(1):88-92. PubMed ID: 38010569
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
